Literature DB >> 2632216

Susceptibility of Brucella melitensis to fluoroquinolones.

S M Qadri1, M Akhtar, Y Ueno, M B al-Sibai.   

Abstract

In vitro activity of four fluoroquinolones and four other antibacterial agents was tested against clinical isolates of Brucella melitensis. Initially all the 146 isolates studied were inhibited by 0.06-0.5 mg/l of ciprofloxacin and fleroxacin and 0.12-0.5 mg/l of pefloxacin or norfloxacin. One of these isolates developed resistance during therapy with ciprofloxacin, with a rise in MIC from 0.06 mg/l to more than 5.0 mg/l. This strain also showed cross-resistance to all other quinolones. All the isolates remained susceptible to tetracycline, gentamicin, rifampicin and trimethoprim-sulfamethoxazole. None of the quinolones showed in vitro synergy with other antibiotics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2632216

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  9 in total

1.  Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.

Authors:  Martine Braibant; Laurence Guilloteau; Michel S Zygmunt
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.

Authors:  M B al-Sibai; M A Halim; M M el-Shaker; B A Khan; S M Qadri
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  In vitro activities of six new fluoroquinolones against Brucella melitensis.

Authors:  I Trujillano-Martín; E García-Sánchez; I M Martínez; M J Fresnadillo; J E García-Sánchez; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 7.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

8.  The TolC homologue of Brucella suis is involved in resistance to antimicrobial compounds and virulence.

Authors:  Diana M Posadas; Fernando A Martín; Julia V Sabio y García; Juan M Spera; M Victoria Delpino; Pablo Baldi; Eleonora Campos; Silvio L Cravero; Angeles Zorreguieta
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

9.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.